

Self-Assembly Nanostructure of Myristoylated ω -Conotoxin MVIIA Increases the Duration of Efficacy and Reduces Side Effects

Xiufang Ding ¹, Yue Wang ^{1,2}, Sida Zhang ¹, Ruihua Zhang ¹, Dong Chen ¹, Long Chen ², Yu Zhang ¹, Shi-Zhong Luo ², Jianfu Xu ^{1,*} and Chengxin Pei ^{1,*}

- 1 State key Laboratory of NBC Protection for Civilian, Beijing 102205, China
2 Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China
* Correspondence: jianfuxu2000@hotmail.com (J.X.); peichengxin@sklnbcpc.cn (C.P.)

Table S1. Particle sizes of the peptides MVIIA and Myr-MVIIA.

peptide	Particle Size (nm)	PDI
MVIIA	48.74 ± 16.07	0.514
Myr-MVIIA	301.83 + 98.09	0.400




Figure S1. (A) HPLC of MVIIA (B) The molecular mass of the MVIIA was determined by ESI-MS.
expected mass: 2639.2, observed mass: [M+2H]²⁺: 1320.84, [M+3H]³⁺: 880.70, [M+4H]⁴⁺: 660.78.




Figure S2. (A) HPLC of Myr-MVIIA (B) The molecular mass of the Myr-MVIIA was determined by ESI-MS. expected mass: 2849.5, observed mass: $[M+2H]/2$: 1425.24, $[M+3H]/3$: 950.83, $[M+4H]/4$: 713.37.